| (Values in U.S. Thousands) | Jun, 2020 | Mar, 2020 | Dec, 2019 | Sep, 2019 | Jun, 2019 |
| Sales | 780 | 680 | 21,910 | 15,250 | 2,810 |
| Sales Growth | +14.71% | -96.90% | +43.67% | +442.70% | -72.88% |
| Net Income | -10,330 | -10,150 | 9,270 | 3,080 | -7,630 |
| Net Income Growth | -1.77% | -209.49% | +200.97% | +140.37% | -108.47% |
Pfenex Inc (PFNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Pfenex Inc. is a clinical-stage biotechnology company developing and commercializing proteins. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis, for the potential treatment of patients with retinal diseases. It leverages its Pf'nex Expression Technology (TM) platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics. Pfenex Inc. is headquartered in San Diego, California.
Fiscal Year End Date: 12/31